Catalyst Event
Novo Nordisk A/S (NVO) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/19/2026, 12:00:00 AM
The U.S. FDA approved Wegovy HD, a new higher 7.2 mg dose of its weight-loss drug semaglutide. The approval was based on the STEP UP trial, which showed significant weight loss. The U.S. launch is expected in April 2026.
Korean Translation
미국 FDA, 체중 감량 약물 세마글루타이드의 새로운 고용량 버전인 위고비 HD(7.2mg)를 승인함. 이번 승인은 상당한 체중 감량 효과를 보인 STEP UP 임상시험에 근거한 것이며, 2026년 4월 미국 출시가 예상됨.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Exelixis Inc (EXEL) · Earnings Release
Exelixis is expected to report its Q1 2026 earnings on or around May 12, 2026, and analysts forecast EPS of approximately $0.73-$0.76; high importance reflects potential volatility from earnings surprises, forecasted and scheduled.
5/12/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol Myers Squibb Q1 2026 results conference call is scheduled for 2026-04-30; as the next earnings catalyst following the strong Q4 2025 outlook, a multi-percent share move is reasonably expected based on typical earnings volatility scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its financial results for the first quarter of 2026 before the market opens on April 29, 2026, followed by a conference call with management; a 5% price impact is estimated for this earnings release, scheduled.
4/29/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM